1,801 Shares in Stryker Corporation $SYK Acquired by Twin City Private Wealth LLC

Twin City Private Wealth LLC acquired a new stake in shares of Stryker Corporation (NYSE:SYK) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,801 shares of the medical technology company’s stock, valued at approximately $593,000.

Several other large investors have also recently added to or reduced their stakes in SYK. VanderPol Investments L.L.C. raised its stake in shares of Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after purchasing an additional 28 shares in the last quarter. KCM Investment Advisors LLC grew its position in Stryker by 1.5% in the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock worth $653,000 after acquiring an additional 28 shares in the last quarter. Rossby Financial LCC increased its stake in shares of Stryker by 6.6% during the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after purchasing an additional 28 shares during the last quarter. Stonebridge Capital Advisors LLC increased its stake in shares of Stryker by 0.4% during the 3rd quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company’s stock worth $2,661,000 after purchasing an additional 29 shares during the last quarter. Finally, Tcfg Wealth Management LLC raised its holdings in shares of Stryker by 2.7% during the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after purchasing an additional 29 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Down 0.5%

Stryker stock opened at $313.38 on Thursday. The business has a 50 day moving average price of $309.89 and a two-hundred day moving average price of $339.15. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The stock has a market cap of $120.14 billion, a price-to-earnings ratio of 36.27, a price-to-earnings-growth ratio of 2.02 and a beta of 0.78. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts forecast that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is currently 40.74%.

Analysts Set New Price Targets

SYK has been the subject of a number of analyst reports. Citigroup reduced their price objective on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. JPMorgan Chase & Co. dropped their target price on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Leerink Partners cut their target price on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. BTIG Research decreased their price target on shares of Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a report on Friday, May 1st. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $361.00 price target on shares of Stryker in a research report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $395.33.

Insiders Place Their Bets

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 323,264 shares of company stock worth $100,659,489 over the last 90 days. Corporate insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.